Patent Insights · Cyclic Peptide Discovery

IL-23R Cyclic Peptide Patents: Scaffold, Conjugation and Exposure

A comparative reading of three published applications, with a focus on what their disclosed structures and experiments can inform in cyclic peptide discovery.

At a Glance

One Target, Several Design Questions

Published IL-23R peptide applications can be read as complementary examples of how a receptor-binding cyclic peptide is defined, decorated and tested. They do not establish that any one modification universally improves oral delivery or half-life. The value of reading them together is to separate the ring-constrained recognition element from the optional groups and linkers that change exposure, distribution and assay behavior.

This page summarizes WO2026041110A1, WO2026067838A1 and WO2026130480A1. The first two public records identify Shanghai Peptidstar Therapeutics as the applicant and disclose polypeptide compounds; the third published application describes IL-23R antagonists and a broader set of substituent and linker embodiments. The applications have distinct priority and filing histories. Their publications should be treated as source material for technical analysis, not as a statement about freedom to operate, patent validity or ownership of every illustrated structure.

ApplicationTechnical focus in this reviewWhat to inspect in the primary textDesign question
WO2026067838A1
Published April 2026
IL-23R-binding polypeptide and cyclic peptide design spaceCore formula, residue definitions, ring connection, compound examples and functional assaysWhich molecular features belong to the recognition scaffold?
WO2026041110A1
Published February 2026
Modified polypeptides including an aromatic appendage in described examplesLinker identity and attachment position, including the disclosed 4-(p-iodophenyl)butyric acid (IPBA) chemistryHow does appendage choice affect activity and exposure-related tests?
WO2026130480A1
Published June 2026
IL-23R antagonist compounds with multiple linker and substituent embodimentsFormula I, the possible Z/L groups, long-chain structures, individual compounds and albumin-containing assaysWhich long-chain variants were actually prepared and how were they evaluated?

Publication dates indicate when each application became public; they are not dates of invention or evidence that an application has been granted. See each record for its priority claims, family and jurisdiction-specific status.

Patent-by-Patent Reading

Three Disclosures, Read at the Level of Actual Embodiments

01 · Cyclic peptide scaffold

WO2026067838A1: Define the Recognition Core

This application describes polypeptide compounds directed at IL-23R. For a design team, the useful first pass is to map its generic formula against concrete examples: residue identity, stereochemistry, cyclization site, ring size, exocyclic tail and any substituents. The generic formula shows a permitted design space; it is not a single experimentally characterized molecule.

In an internal design exercise, the application can motivate a target-interface assessment: which residues may maintain receptor engagement, where cyclic constraint might orient the pharmacophore, and which positions may tolerate substitution. These are hypotheses for separate structural and experimental work. A virtual pose cannot prove the binding mode, and receptor affinity does not by itself establish pathway inhibition, selectivity or oral exposure.

Read the compound examples and assay conditions alongside the claims. The comparison is most informative when the same test system, concentration range and definition of activity are used. When a numerical result is missing or only a broad category is reported, it should remain an uncertainty in any cross-patent ranking.

02 · Aromatic appendage

WO2026041110A1: Examine the Linker Rather Than Assuming Lipidation

The synthesis description explicitly uses 4-(p-iodophenyl)butyric acid, abbreviated here as IPBA, in several examples. That aromatic acid is chemically distinct from a conventional long-chain fatty acid. It is therefore more precise to discuss the particular appendage and attachment position than to describe this application simply as a “fatty-acid conjugate” patent.

Relevant comparisons include modified versus unmodified peptide, different points of attachment, preserved IL-23R antagonism in functional assays and changes observed in an albumin-containing system. An aromatic appendage may be investigated for exposure-related properties, but the presence of IPBA alone does not prove a mechanism of albumin binding or an extension of systemic half-life. Those require appropriately designed binding and pharmacokinetic experiments.

For a computational service workflow, this application highlights a multi-objective problem: hold the peptide recognition motif, vary the appendage and linker, then compare receptor binding, pathway inhibition, physicochemical properties and measured exposure. The assay matrix should distinguish protein binding from free-drug activity and should not use a single potency number as the sole selection criterion.

03 · Linker and long-chain variants

WO2026130480A1: Compare Actual Long-Chain Embodiments

The application describes IL-23R antagonist compounds represented by a cyclic segment and further residues, with alternative substituent and linker groups. Its submitted Chinese application text illustrates, among other options, a long hydrocarbon chain with a terminal carboxyl group connected through a more elaborate linker. It also illustrates other nonidentical groups. Thus “long-chain lipidated embodiments” is a useful description of part of the disclosure; “the patent is a C18 fatty-acid peptide” would overstate both the breadth and the specific structural assignment.

The text describes synthesis and testing, including activity in albumin-containing systems. The experiment matters because peptide modification can change both protein-bound fraction and the apparent activity observed in an assay with albumin. It does not allow a reader to infer an identical pharmacokinetic effect for every compound covered by a generic formula. A candidate-level comparison should pair the exact structure with its measured assay conditions and any reported in vivo data.

In the submitted scan, page 10 provides a useful structure-level starting point for reviewing linkers and long-chain variants; the abstract appears on the final page. The exact carbon count of each illustrated substituent should be checked against the specific structure and chemical naming before using “C18” in a title or caption. The string “C18” in text searches often denotes the reversed-phase chromatography medium used during purification and is not evidence of an 18-carbon conjugate.

Cross-Patent Comparison

A Practical Map for a New IL-23R Program

1 · Binding interfaceAssess receptor surface, ligand competition, selectivity and any differentiating pocket or epitope.
2 · Ring scaffoldDesign or screen constrained peptides, then confirm binding and pathway inhibition.
3 · Exposure designCompare attachment sites, IPBA-like aromatic groups and supported long-chain alternatives.
4 · Evidence loopMeasure activity with and without albumin where relevant, permeability, stability and PK.
Interpretation boundary: The three applications are not a proven linear sequence in which one is the “mother patent” and the others are formal improvements of the same specific compound. Their technical themes can be compared as scaffold, appendage and exposure questions, while claim scope, common priority and patent-family relationships require separate legal review.

The same distinction matters for oral cyclic peptide research. A longer half-life after systemic dosing is not proof of gastrointestinal permeability or oral bioavailability. Conversely, a permeability-favorable scaffold may lose receptor potency after conjugation. For candidate selection, compare each modification in a matched assay panel and define the target product profile before choosing which property to optimize first.

Relevant Workflows

From a Public Patent Question to Testable Research

Target & Hit Finding

Review IL-23R binding-interface evidence and design a differentiated cyclic peptide library or a focused virtual screen. Compare hypotheses about contact residues without presenting a docking pose as validated binding.

Library design service →

Oral & Lead Optimization

Explore ring and side-chain modifications together with permeability, solubility, stability and synthesis risk. Use an explicit multi-objective ranking when potency and developability move in different directions.

Lead optimization service →

Validation & Exposure

Plan compound-level synthesis, structural confirmation, receptor and pathway assays, albumin binding where relevant, and PK measurements. Compare modified and parent peptides on the same experimental basis.

Experimental validation service →

Half-life-extension and albumin-binding design can be scoped as a dedicated project module. Until a dedicated service page is published, contact the team with the intended peptide, attachment chemistry and decision endpoint. Patent text is a starting source for technical questions; independent design, synthesis and experimental work are needed to establish performance.

Primary Sources

Read the Published Applications

  1. WO2026067838A1 — Polypeptide compound and use thereof, published April 2, 2026.
  2. WO2026041110A1 — Polypeptide compound and use thereof, published February 26, 2026.
  3. WO2026130480A1 — Interleukin receptor antagonist and application thereof, published June 25, 2026.

This page is a technical reading of public applications, not a patentability or freedom-to-operate opinion. Experimental results and chemical structures remain attributable to the applicants; no proprietary CD ComputaBio IL-23R compound is claimed here.

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.